Actively Recruiting
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies
Led by Ruijin Hospital · Updated on 2024-12-11
40
Participants Needed
1
Research Sites
144 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for gastrointestinal malignancies.
CONDITIONS
Official Title
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathological and clinical diagnosis of gastrointestinal malignancies requiring immunotherapy or combination immunotherapy after evaluation according to clinical guidelines.
- Signed and dated informed consent form.
- Commitment to comply with research procedures and co-operation in the implementation of the full research process.
- The patient is in good general condition with an expected survival of > 6 months.
- Aged 18-75 years old.
You will not qualify if you...
- Patients with serious illnesses that researchers consider unsuitable for participation, such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction.
- Intestinal perforation or complete intestinal obstruction.
- Pregnant women, women who may be pregnant, and women who are breastfeeding.
- Persons who are non-compliant with study requirements.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
Shanghai, Shanghai Municipality, China, 200001
Actively Recruiting
Research Team
J
Jiajia Hu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here